Patents by Inventor Bernhard Peball

Bernhard Peball has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR TREATING A GD2 POSITIVE CANCER
    Publication number: 20230340148
    Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.
    Type: Application
    Filed: September 19, 2022
    Publication date: October 26, 2023
    Applicant: APEIRON BIOLOGICS AG
    Inventors: Hans LOIBNER, Manfred SCHUSTER, Evelyne JANZEK-HAWLAT, Susanne WIEDERKUM, Bernhard PEBALL, Stefan STRANNER, Oliver MUTSCHLECHNER, Franz GROISS, Ruth LADENSTEIN, Holger LODE
  • Method for treating a GD2 positive cancer
    Patent number: 11447565
    Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: September 20, 2022
    Assignee: APEIRON BIOLOGICS AG
    Inventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat, Susanne Wiederkum, Bernhard Peball, Stefan Stranner, Oliver Mutschlechner, Franz Groiss, Ruth Ladenstein, Holger Lode
  • Method for producing ACE2 polypeptide
    Patent number: 10716833
    Abstract: The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: July 21, 2020
    Assignee: APEIRON BIOLOGICS AG
    Inventors: Manfred Schuster, Hans Loibner, Evelyne Janzek-Hawlat, Bernhard Peball, Stefan Stranner, Bettina Wagner, Robert Weik
  • METHOD OF TREATING LUNG, KIDNEY, OR HEART DISEASE WITH A RECOMBINANT ACE2 POLYPEPTIDE DIMER
    Publication number: 20180289779
    Abstract: The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer.
    Type: Application
    Filed: December 6, 2017
    Publication date: October 11, 2018
    Inventors: Manfred Schuster, Hans Loibner, Evelyne Janzek-Hawlat, Bernhard Peball, Stefan Stranner, Bettina Wagner, Robert Weik
  • METHOD FOR TREATING A GD2 POSITIVE CANCER
    Publication number: 20180134801
    Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.
    Type: Application
    Filed: September 11, 2017
    Publication date: May 17, 2018
    Applicant: APEIRON BIOLOGICS AG
    Inventors: Hans LOIBNER, Manfred SCHUSTER, Evelyne JANZEK-HAWLAT, Susanne WIEDERKUM, Bernhard PEBALL, Stefan STRANNER, Oliver MUTSCHLECHNER, Franz GROISS, Ruth LADENSTEIN, Holger LODE
  • Method for treating a GD2 positive cancer
    Patent number: 9777068
    Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: October 3, 2017
    Assignee: APEIRON BIOLOGICS AG
    Inventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat, Susanne Wiederkum, Bernhard Peball, Stefan Stranner, Oliver Mutschlechner, Franz Groiss, Ruth Ladenstein, Holger Lode
  • Modified ACE2 polypeptides
    Patent number: 9757433
    Abstract: The present invention relates to modified angiotensin converting enzyme 2 (ACE2) polypeptides and pharmaceutical and analytical uses thereof. In particular, the present invention relates to Zn2+ depleted-, Zn2+ free-, mixed metal- and metal ion substituted-ACE2 as well as methods for the manufacture of these variants and uses thereof, such as therapeutic and analytic uses of these ACE2 variants.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: September 12, 2017
    Assignee: Apeiron Biologicals AG
    Inventors: Hans Loibner, Bernhard Peball, Manfred Schuster, Stefan Stranner
  • Modified ACE2 polypeptides
    Publication number: 20150353910
    Abstract: The present invention relates to modified angiotensin converting enzyme 2 (ACE2) polypeptides and pharmaceutical and analytical uses thereof. In particular, the present invention relates to Zn2+ depleted-, Zn2+ free-, mixed metal- and metal ion substituted-ACE2 as well as methods for the manufacture of these variants and uses thereof, such as therapeutic and analytic uses of these ACE2 variants.
    Type: Application
    Filed: January 13, 2014
    Publication date: December 10, 2015
    Inventors: Hans LOIBNER, Bernhard PEBALL, Manfred SHUSTER, Stefan STRANNER
  • Method for Tretaing a GD2 Positive Cancer
    Publication number: 20150139942
    Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.
    Type: Application
    Filed: July 31, 2012
    Publication date: May 21, 2015
    Applicant: APEIRON BIOLOGICS AG
    Inventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat, Susanne Wiederkum, Bernhard Peball, Stefan Stranner, Oliver Mutschlechner, Franz Groiss, Ruth Ladenstein, Holger Lode
  • Treatment of tumors
    Patent number: 8946162
    Abstract: The invention provides for innovative improvements in tumor therapy, particularly therapies which are conducted using endogenous substances and which have no or only mild side-effects. Accordingly the present invention relates to methods of treating or preventing tumor diseases other than lung cancer comprising administering a polypeptide with an angiotensin-converting-enzyme-2 (ACE2) activity.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: February 3, 2015
    Inventors: Evelyne Janzek-Hawlat, Hans Loibner, Manfred Schuster, Bernhard Peball
  • ACE2 POLYPEPTIDE
    Publication number: 20140099297
    Abstract: The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer.
    Type: Application
    Filed: September 13, 2013
    Publication date: April 10, 2014
    Applicant: Apeiron Biologics AG
    Inventors: Manfred Schuster, Hans Loibner, Evelyne Janzek-Hawlat, Bernhard Peball, Stefan Stranner, Bettina Wagner, Robert Weik
  • Recombinant ACE2 polypeptide dimer
    Patent number: 8586319
    Abstract: The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: November 19, 2013
    Assignee: Apeiron Biologics AG
    Inventors: Manfred Schuster, Hans Loibner, Evelyne Janzek-Hawlat, Bernhard Peball, Stefan Stranner, Bettina Wagner, Robert Weik
  • TREATMENT OF TUMORS
    Publication number: 20110033524
    Abstract: The invention provides for innovative improvements in tumour therapy, particularly therapies which are conducted using endogenous substances and which have no or only mild side-effects. Accordingly the present invention relates to methods of treating or preventing tumor diseases other than lung cancer comprising administering a polypeptide with an angiotensin-converting-enzyme-2 (ACE2) activity.
    Type: Application
    Filed: April 7, 2009
    Publication date: February 10, 2011
    Inventors: Evelyne Janzek-hawlat, Hans Loibner, Manfred Schuster, Bernhard Peball
  • ACE2 Polypeptide
    Publication number: 20100310546
    Abstract: The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life.
    Type: Application
    Filed: June 12, 2008
    Publication date: December 9, 2010
    Applicant: APEIRON BIOLOGICS AG
    Inventors: Manfred Schuster, Hans Loibner, Evelyne Janzek-Hawlat, Bernhard Peball, Stefan Stranner, Bettina Wagner, Robert Weik